BioScrip Board Of Director R. Carter Pate Becomes NACD Board Leadership Fellow
ELMSFORD, N.Y., Sept. 9, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company") today announced that R. Carter Pate, a member of BioScrip's Board of Directors since May 2015, has become an NACD Board Leadership Fellow, the highest level of credentialing for corporate directors and corporate governance professionals offered by The National Association of Corporate Directors. He joins more than 50 other corporate directors from leading corporations around the world who also earned the prestigious credential during the second quarter of 2015.
"It is an honor to join the distinguished and diverse group of individuals who make up NACD's Fellowship program," said Pate. "We share a commitment to advancing the highest standards of boardroom leadership, and the insights I've gained through NACD's Fellowship program will be key to my professional growth as a director and the contributions I make to BioScrip."
"As the emphasis on corporate governance intensifies, having one of our board members recognized with such respected credentials demonstrates how seriously we take fiduciary responsibility," said Myron Z. Holubiak, Chairman of the Board of Directors of BioScrip. "It is yet another indication of the strength of the Board of Directors we have assembled to oversee and support the implementation of the Company's operations and financial improvement plan. Moreover, it is imperative that we operate with the highest integrity and transparency as we continue to execute our strategy to streamline the Company so as to effect meaningful change and drive shareholder value."
An NACD Fellowship, considered the definitive director credential, is a comprehensive program of study developed to educate directors about perennial and emerging boardroom issues and best practices. Completion of this rigorous program demonstrates a director's serious commitment to exemplary corporate governance.
Candidates complete a strong foundation course which focuses on topical matters and committee-specific issues, followed by additional NACD education within a 12-month period. NACD Fellows renew their status every year, maintaining and advancing their knowledge with continuous learning and peer-led collaboration.
R. Carter Pate, CPA, has been a director of the Company since May 2015. Mr. Pate serves as Chair of the Company's Audit Committee and its newly-formed Financial Improvement Implementation Committee, and he is a member of the Company's Management Development and Compensation Committee.
Mr. Pate previously served as Chief Executive Officer of MV Transportation, Inc., the largest privately-owned passenger transportation contracting firm based in the U.S. ("MV") from 2011 to 2014 and continues to serve as an independent strategic advisor to MV. From 1996 to 2011, Mr. Pate was employed by PricewaterhouseCoopers, LLP ("PwC"), where he held increasingly responsible positions including the U.S. and Global Managing Partner of PwC's Capital Projects and Infrastructure practice, the Global and U.S. Managing Partner of PwC's Health Care Practice, and as a Partner and Leader in PwC's U.S. Restructuring Practices.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Forward-Looking Statements – Safe Harbor
This press release includes statements that may constitute "forward-looking statements," including projections of certain measures of the Company's results of operations, projections of future levels of certain charges and expenses, and other statements regarding the Company's financial improvement plan and strategy. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "outlook," "aim," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause or contribute to such differences include but are not limited to risks associated with: the Company's ability implement its financial improvement plan to reduce operating costs and focus its business on its Infusion Services segment; reductions in federal, state and commercial reimbursement for the Company's products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission. The Company does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company's situation may change in the future. All of the forward-looking statements herein are qualified by these cautionary statements.
Logo - http://photos.prnewswire.com/prnh/20130117/NY44138LOGO
SOURCE BioScrip, Inc.
Share this article